Okeiro Secures €10 Million to Advance AI-Driven Precision Medicine Platform for Transplantation and Chronic Diseases
核心洞察
Okeiro (搜索) (formerly Predict4Health) has raised €10 million in funding led by Alven (搜索), Forepont Capital Partners (搜索), and Red River West (搜索) to expand its AI-powered clinical decision support platform internationally.
The company's proprietary iBox (搜索) algorithm, recognized as a surrogate endpoint by FDA and EMA, enables early prediction of transplant rejection and has already been implemented in leading French transplant centers.
Okeiro (搜索) is conducting a multi-center randomized clinical trial across 16 hospitals in 6 countries to validate its technology's effectiveness compared to standard care protocols.
Paris-based precision medicine company Okeiro (搜索) has secured €10 million in funding to accelerate the development and international expansion of its AI-powered platform for transplantation and chronic disease management. The financing round, announced on April 10, 2025, was led by Alven (搜索), Forepont Capital Partners (搜索), and Red River West (搜索).
Okeiro (搜索), formerly known as Predict4Health, has developed an advanced clinical decision support platform that leverages artificial intelligence to prevent organ failure, with applications for kidneys, lungs, heart, and liver. The funding will enable the company to strengthen its presence in French hospitals, expand across Europe, and prepare for entry into the U.S. market this year.
Revolutionary iBox Algorithm Transforms Transplant Medicine
At the core of Okeiro (搜索)'s platform is the groundbreaking iBox (搜索) algorithm—a clinically validated predictive model that has been marked as a medical device and qualified as a surrogate endpoint by both the FDA and EMA. This proprietary technology was developed in collaboration with APHP and INSERM, France's premier medical research institution.
The iBox (搜索) algorithm enables physicians to identify post-transplant complications years before they occur, revolutionizing patient monitoring and treatment protocols. This early detection capability has significant implications for the 850 million people worldwide affected by kidney disease alone, which accounts for 70% of all organ transplants. With over 250,000 patients currently on waiting lists for life-saving transplants, the need for innovative solutions is urgent.
"We're grateful to our new investors for their strategic backing in this pivotal growth phase," said Pierrick Arnal, CEO and co-founder of Okeiro (搜索). "Backed by our strong science and clinically validated AI models, Okeiro is set to transform transplant medicine globally. We'll deliver on our mission to create a new standard where breakthrough technology elevates patient care while accelerating clinical research for drug development in this critical field."
Clinical Validation and Market Traction
Okeiro (搜索)'s platform has already been implemented in leading transplant centers across France, benefiting thousands of patients. The technology has achieved national reimbursement status through the French National Health Insurance, validating both its clinical utility and economic value within established remote monitoring frameworks.
Dr. Ismail Kola, Partner at Forepont Capital Partner, highlighted the significance of Okeiro (搜索)'s innovation: "We're delighted to invest in Okeiro, whose groundbreaking algorithm predicts kidney transplant rejection years before occurrence. This innovation is so significant that regulatory agencies now accept it as a surrogate endpoint in clinical trials, dramatically reducing development costs and time-to-market for new therapies."
The company is currently conducting a randomized clinical trial across 16 hospital centers in 6 countries (France, Germany, United Kingdom, Austria, Israel, and Spain) to further validate the effectiveness of its technology. The study compares outcomes between physicians using the platform and those applying standard care protocols. According to Okeiro (搜索), interim results are very positive, and the study will be completed within a few months.
Addressing a Growing Global Health Crisis
Chronic Kidney Disease (搜索) (CKD) represents a significant and growing global health challenge. According to Luc-Emmanuel Barreau, Partner at Red River West (搜索), "By 2040, CKD will rank 5th in global mortality, and is even more prevalent in the US with 15% of the population affected by some form of CKD vs 10% for the rest of the world."
François Meteyer, Partner at Alven (搜索), emphasized the strategic importance of Okeiro (搜索)'s approach: "At Alven, we like to back clinical software companies with deep medical-grade IP targeting the US market and aligning industry vertical stakeholders around new game-changing platforms. In the wake of what we did with Cardiologs in cardiology a few years ago, we're thrilled to back Okeiro's team and help them scale their precision medicine solution and software business operations to become a major player in the chronic diseases category."
Future Development and Expansion Plans
Beyond strengthening its market presence, Okeiro (搜索) plans to use part of the new funding to develop additional AI tools that will further improve the precision of diagnostics, therapeutic recommendations, and acceleration of clinical research in end-stage chronic disease and transplant patients.
The company's rebranding from Predict4Health to Okeiro (搜索) reflects its evolving mission. The new name, inspired by the Greek "Kairos" meaning "the critical moment," emphasizes Okeiro's focus on supporting healthcare professionals in making decisive decisions with the right information to optimize patient care.
Founded by a team of experts in medicine, data science, and artificial intelligence, Okeiro (搜索) aims to redefine the standard of care for patients with advanced chronic diseases and transplants by improving diagnosis, therapeutic recommendations, quality and safety of patient monitoring, and accelerating therapeutic innovation through data-driven approaches.